Bear Stearns 18 th Annual Investor Conference September 12, 2005 RJ Kirk (Chairman and CEO) Krish Krishnan (CFO/COO) Exhibit 99.1
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation may contain forward-looking statements that reflect management’s current views as to the Company’s clinical trials, regulatory approval process, product development, research programs and other future events and operations. These forward-looking statement
Slide 3: Investment Thesis
Investment Thesis A platform technology yielding proprietary products that offer significant clinical advantages with low technical risk and shorter development pathway, facing timely market demand, in a favorable regulatory climate.
Slide 4: New River's Carrierwave™ Technology
New River’s Carrierwave™ Technology Active Drug Peptide(s) New Molecular Entity n Novel, proprietary drugs are created by covalently binding an active drug to one or more natural amino acids that are Generally Regarded As Safe (GRAS) n Active drug is released from conjugate enzymatically and is abso
Slide 5: Potential Bioactive Enhancements
Potential Bioactive Enhancements n Increased bioavailability n Increased stability n Reduced variability n Decreased toxicity n Abuse resistance n Overdose protection
Slide 6: Targeting product classes that need improvement
NSAIDS OPIOIDS THYROID HORMONE REPLACEMENT ANTIVIRALS STIMULANTS CARDIOVASCULAR Targeting product classes that need improvement
Slide 7: Financials
Financials n Anticipated cash burn for the rest of 2005 is estimated to be between $8 million and $12 million n Cash position at the end of August 2005 was approximately $56 million n Anticipated milestones from Shire Pharmaceuticals, Inc. • US$50 million from Shire upon acceptance of the NDA on NRP
Slide 8: Product pipeline and clinical progress
Product pipeline and clinical progress
Slide 9: NRP104
NRP104 n A conditionally bioreversible derivative of d-amphetamine n Potential indications: ADHD (Pediatric, Adolescent, Adult), treatment for certain depressive disorders, treatment for addiction to stimulants n Non-clinical and clinical studies to date have met their desired objectives n Phase 3 c
Slide 10: NRP290
NRP290 n A conditionally bioreversible derivative of hydrocodone n Potential indications: Pain (moderate to moderately severe) n Non-clinical studies to date have met their desired objectives n PK clinical study on NRP290 completed • Design: A single dose pharmacokinetic study to assess oral bioavai
Slide 11: Other
Other Compound Indication Timeline Technology NRP388 Chronic Pain and Tolerance IND in Q1 2006 n Licensed from the Gallo Clinic NRP409 Hypothyroidism IND in Q2 2006 n Carrierwave™